• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics wins CE mark for remote glucose monitoring app for Android users

December 21, 2021 By Sean Whooley

Eversense CGM Senseonics
The Eversense CGM [Image courtesy of Senseonics]
Senseonics (NYSE:SENS) announced today that its Eversense NOW remote monitoring app for Android received CE mark approval.

Germantown, Maryland-based Senseonics already received such approval for the Eversense NOW iOS platform and can now offer it in Europe on the Android operating system. The company expects to make the Eversense NOW remote monitoring app for Android available in the first quarter of 2022 on the Google Play Store.

Eversense NOW offers real-time glucose data and alerts in tandem with the Eversense XL continuous glucose monitoring (CGM) system that measures glucose levels in persons 18 years of age and older with diabetes for up to 180 days. Senseonics designed the system to complement, not replace, fingersticks.

Data presented earlier this year demonstrated strong accuracy, with the next-generation Eversense matching performance levels compared to the current 90-day sensor available in the U.S., but with reduced calibration, down to one per day, with duration extended to 180 days.

“We’re pleased to offer yet another tool for our Eversense users in Europe, now enabling access to this important feature for all our customers,” Senseonics President & CEO Tim Goodnow said in a news release. “With the Eversense NOW app, Eversense users can enjoy the added peace of mind that comes with knowing friends and family can remotely view real-time glucose data, see trend graphs, and receive real-time glucose alerts from anywhere.”

Filed Under: Big Data, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Regulatory/Compliance, Technology Tagged With: Senseonics

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS